These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 7831649)

  • 1. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis.
    Lindmarker P; Holmström M; Granqvist S; Johnsson H; Lockner D
    Thromb Haemost; 1994 Aug; 72(2):186-90. PubMed ID: 7831649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis.
    Fiessinger JN; Lopez-Fernandez M; Gatterer E; Granqvist S; Kher A; Olsson CG; Söderberg K
    Thromb Haemost; 1996 Aug; 76(2):195-9. PubMed ID: 8865530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis.
    Luomanmäki K; Grankvist S; Hallert C; Jauro I; Ketola K; Kim HC; Kiviniemi H; Koskivirta H; Sörskog L; Vilkko P
    J Intern Med; 1996 Aug; 240(2):85-92. PubMed ID: 8810934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous and subcutaneous administration of Fragmin in deep venous thrombosis.
    Lockner D; Bratt G; Törnebohm E; Aberg W; Granqvist S
    Haemostasis; 1986; 16 Suppl 2():25-9. PubMed ID: 3744133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT).
    Bratt G; Aberg W; Johansson M; Törnebohm E; Granqvist S; Lockner D
    Thromb Haemost; 1990 Dec; 64(4):506-10. PubMed ID: 1964751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group.
    Kirchmaier CM; Wolf H; Schäfer H; Ehlers B; Breddin HK
    Int Angiol; 1998 Sep; 17(3):135-45. PubMed ID: 9821025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis.
    Riess H; Koppenhagen K; Tolle A; Kemkes-Matthes B; Gräve M; Patek F; Drexler M; Siemens HJ; Harenberg J; Weidinger G; Brom J; Haas S;
    Thromb Haemost; 2003 Aug; 90(2):252-9. PubMed ID: 12888872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 6-month venographic follow-up in 164 patients with acute deep vein thrombosis.
    Holmström M; Lindmarker P; Granqvist S; Johnsson H; Lockner D
    Thromb Haemost; 1997 Aug; 78(2):803-7. PubMed ID: 9268175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis.
    Simonneau G; Charbonnier B; Decousus H; Planchon B; Ninet J; Sie P; Silsiguen M; Combe S
    Arch Intern Med; 1993 Jul; 153(13):1541-6. PubMed ID: 8391792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
    Harenberg J; Stehle G; Blauth M; Huck K; Mall K; Heene DL
    Semin Thromb Hemost; 1997; 23(1):83-90. PubMed ID: 9156415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fragmin once or twice daily subcutaneously in the treatment of deep venous thrombosis of the leg.
    Holmoström M; Berglund MC; Granquist S; Bratt G; Törnebohm E; Lockner D
    Thromb Res; 1992 Jul; 67(1):49-55. PubMed ID: 1332213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism.
    Prandoni P; Carnovali M; Marchiori A;
    Arch Intern Med; 2004 May; 164(10):1077-83. PubMed ID: 15159264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency of major hemorrhage in patients treated with unfractionated intravenous heparin for deep venous thrombosis or pulmonary embolism: a study in routine clinical practice.
    Zidane M; Schram MT; Planken EW; Molendijk WH; Rosendaal FR; van der Meer FJ; Huisman MV
    Arch Intern Med; 2000 Aug 14-28; 160(15):2369-73. PubMed ID: 10927736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of deep venous thrombosis. Comparative study of a low molecular weight heparin fragment (Fragmin) by the subcutaneous route and standard heparin by the continuous intravenous route. A multicenter study].
    Aiach M; Fiessinger JN; Vitoux JF; Derlon A; Grollier G; Le Querrec A; Gouault-Heilmann M; Huet Y; Franco A; Polack B; Pouzol P; Dubois A; Schved JF; Boneu B; Guittard J; Sie P; Heilmann JJ; Kher A; Haye I
    Rev Med Interne; 1989; 10(4):375-81. PubMed ID: 2552552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous low-molecular-weight heparin fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomized pilot study.
    Meyer G; Brenot F; Pacouret G; Simonneau G; Gillet Juvin K; Charbonnier B; Sors H
    Thromb Haemost; 1995 Dec; 74(6):1432-5. PubMed ID: 8772215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial.
    Lopaciuk S; Meissner AJ; Filipecki S; Zawilska K; Sowier J; Ciesielski L; Bielawiec M; Glowinski S; Czestochowska E
    Thromb Haemost; 1992 Jul; 68(1):14-8. PubMed ID: 1325076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experiences in the administration of a low molecular weight heparin (Fragmin, Kabi-Vitrum) to healthy volunteers and in the treatment of established deep venous thrombosis.
    Bratt GA; Törnebohm E; Johanson M; Aberg W; Granqvist S; Lockner D
    Acta Chir Scand Suppl; 1988; 543():96-100. PubMed ID: 2847465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors and coagulation parameters in relationship to phlebographic response and clinical outcome in the treatment of acute deep vein thrombosis.
    Breddin HK; Kadziola Z; Scully M; Nakov R; Misselwitz F; Kakkar VV
    Thromb Haemost; 2003 Feb; 89(2):272-7. PubMed ID: 12574806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis.
    Ramacciotti E; Araújo GR; Lastoria S; Maffei FH; Karaoglan de Moura L; Michaelis W; Sandri JL; Dietrich-Neto F;
    Thromb Res; 2004; 114(3):149-53. PubMed ID: 15342210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.